Literature DB >> 26373393

Up-regulation of microRNA-16 in Glioblastoma Inhibits the Function of Endothelial Cells and Tumor Angiogenesis by Targeting Bmi-1.

Fanfan Chen, Lei Chen, Hua He, Weiyi Huang, Run Zhang, Peng Li, Yicheng Meng, Xiaodan Jiang1.   

Abstract

BACKGROUND: Angiogenesis is an important process facilitating the growth of glioblastoma (GBM). It also has drawn great attention in the treatment of GBM. GBM angiogenesis is closely related to the function of endothelial cells. microRNAs can affect the activities of endothelial 10 cells directly, or indirectly through the interaction of tumor cells and endothelial cells. However, the mechanism underlying the interaction of GBM cells regulated by specific microRNA with endothelial cells and following angiogenesis requires further research. In published articles, microRNA-16 acted as a tumor suppressor in multiple types of cancers including glioma, but the role in glioma angiogenesis has not been well elucidated.
METHODS: The expression of microRNA-16 was detected in human GBM samples and normal brain tissues. microRNA-16 was transfected to GBM cell line U87 and A172 then the function of endothelial cells co-cultured with U87/A172 (miR-16 or control) were observed in vitro. Expression of VEGF family in vitro and the effect of microRNA-16 on GBM angiogenesis in vivo were also investigated.
RESULTS: microRNA-16 is down-regulated in human GBM samples in contrast to the normal brain tissues. Overexpression of microRNA- 16 in the A172 and U87 GBM cell lines inhibited the activities of co-cultured endothelial cells, including proliferation, migration, extension and tubule formation. Further experiments of dual luciferase assays verified microRNA-16 directly targeting Bmi-1. microRNA-16 down-regulated the expression of vascular endothelial growth factor VEGF-A and VEGF- C which were closely related to the angiogenesis of GBM. Moreover, less vascular formed in the section of neoplasm of the microRNA- transduced group than the control group in vivo.
CONCLUSIONS: Collectively, these findings indicate that loss of microRNA-16 may favor glioma angiogenesis, on the contrary overexpression of microRNA-16 in GBM cells plays a critical role in repressing endothelial function and angiogenesis by targeting Bmi-1. microRNA-16 may be a potential therapeutic agent in the treatment of GBM.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26373393     DOI: 10.2174/1871520615666150916092251

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  13 in total

1.  Identifying survival-associated modules from the dysregulated triplet network in glioblastoma multiforme.

Authors:  Jia-Bin Wang; Feng-Hua Liu; Jian-Hang Chen; Hai-Tao Ge; Lu-Yan Mu; Hong-Bo Bao; Zhi-Guo Lin
Journal:  J Cancer Res Clin Oncol       Date:  2017-02-06       Impact factor: 4.553

Review 2.  Targeting oncomiRNAs and mimicking tumor suppressor miRNAs: Νew trends in the development of miRNA therapeutic strategies in oncology (Review).

Authors:  Roberto Gambari; Eleonora Brognara; Demetrios A Spandidos; Enrica Fabbri
Journal:  Int J Oncol       Date:  2016-05-04       Impact factor: 5.650

3.  MiRNA-16 inhibited oral squamous carcinoma tumor growth in vitro and in vivo via suppressing Wnt/β-catenin signaling pathway.

Authors:  Lijun Liu; Han Jiang; Jin Zhao; Hao Wen
Journal:  Onco Targets Ther       Date:  2018-08-23       Impact factor: 4.147

Review 4.  Regulators at Every Step-How microRNAs Drive Tumor Cell Invasiveness and Metastasis.

Authors:  Tomasz M Grzywa; Klaudia Klicka; Paweł K Włodarski
Journal:  Cancers (Basel)       Date:  2020-12-10       Impact factor: 6.639

Review 5.  MicroRNAs in glioblastoma multiforme pathogenesis and therapeutics.

Authors:  Amanda Shea; Varsha Harish; Zainab Afzal; Juliet Chijioke; Habib Kedir; Shahnoza Dusmatova; Arpita Roy; Malathi Ramalinga; Brent Harris; Jan Blancato; Mukesh Verma; Deepak Kumar
Journal:  Cancer Med       Date:  2016-06-10       Impact factor: 4.452

6.  Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment.

Authors:  Arnold Bolomsky; Karin Schlangen; Wolfgang Schreiner; Niklas Zojer; Heinz Ludwig
Journal:  J Hematol Oncol       Date:  2016-03-02       Impact factor: 17.388

7.  Bmi‑1‑targeting suppresses osteosarcoma aggressiveness through the NF‑κB signaling pathway.

Authors:  Jiaguo Liu; Bin Luo; Meng Zhao
Journal:  Mol Med Rep       Date:  2017-09-28       Impact factor: 2.952

Review 8.  New insights into the regulatory role of microRNA in tumor angiogenesis and clinical implications.

Authors:  Ye Wang; Liya Wang; Cheng Chen; Xiaoyuan Chu
Journal:  Mol Cancer       Date:  2018-02-07       Impact factor: 27.401

9.  Hypoxia, Inflammation and Necrosis as Determinants of Glioblastoma Cancer Stem Cells Progression.

Authors:  Marco Papale; Mariachiara Buccarelli; Cristiana Mollinari; Matteo A Russo; Roberto Pallini; Lucia Ricci-Vitiani; Marco Tafani
Journal:  Int J Mol Sci       Date:  2020-04-11       Impact factor: 5.923

Review 10.  Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.

Authors:  Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.